Otsuka Holdings Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal First Half of 2021 and Full Year Ending December 31, 2021
February 12, 2021 at 05:30 am EST
Share
Otsuka Holdings Co., Ltd. provided consolidated earnings guidance for the fiscal first half of 2021 and full year ending December 31, 2021. For the first half, the company expects revenue to be JPY 690,000 million, operating profit to be JPY 100,000 million, profit for the period to be JPY 77,500 million and basic earnings per share to be JPY 140.13.
For the year, the company expects revenue to be JPY 1,423,000 million, operating profit to be JPY 192,000 million, profit for the period to be JPY 149,000 million and basic earnings per share to be JPY 269.20.
Otsuka Holdings Co, Ltd. is a holding company organised around 4 areas of activity:
- manufacture and sale of pharmaceutical products (65.2% of sales): prescription drugs and intravenous solutions mainly for the treatment of central nervous system disorders, cancer, cardiovascular, gastrointestinal and ophthalmic diseases. In addition, the group sells diagnostic products and medical devices;
- manufacture and sale of nutraceutical products (25.1%): functional foods and beverages, OTC products, nutritional supplements;
- production of mineral waters, beverages and foods (2.1%);
- other (7.5%): manufacture of functional chemicals and fine chemicals, provision of logistics services, manufacture of electronic products, etc.
Net sales by source of income are divided between sales of products (93.8%), sales of licences and royalties (1.8%) and other (4.4%).
Net sales are distributed geographically as follows: Japan (43.2%), North America (34%),
OTSUKA HOLDINGS CO., LTD. 
